Skip to main content

Press Releases

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Date Title
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
-- Trial to Enroll Approximately 15 Patients with Psoriasis -- Top-Line Results Expected in Third Quarter of 2018 WESTLAKE VILLAGE, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s
Toggle Summary Sienna Biopharmaceuticals to Present at J.P. Morgan Healthcare Conference
WESTLAKE VILLAGE, Calif. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the 36 th Annual J.P.